Cargando…

Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma

Steroid 5α-reductase type I (SRD5A1) is a validated oncogene in many sex hormone-related cancers, but its role in multiple myeloma (MM) remains unknown. Based on gene expression profiling (GEP) of sequential MM samples during the disease course, we found that the aberrant expression of SRD5A1 was co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dou, Renjie, Qian, Jinjun, Wu, Wei, Zhang, Yanxin, Yuan, Yuxia, Guo, Mengjie, Wei, Rongfang, Yang, Shu, Jurczyszyn, Artur, Janz, Siegfried, Beksac, Meral, Gu, Chunyan, Yang, Ye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904855/ https://www.ncbi.nlm.nih.gov/pubmed/33627630 http://dx.doi.org/10.1038/s41419-021-03510-4

Ejemplares similares

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma
por: Gu, Chunyan, et al.
Publicado: (2021)

Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2020)

Corrigendum: Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma
por: Chen, Ying, et al.
Publicado: (2021)

HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA
por: Jiang, Fengjie, et al.
Publicado: (2021)

Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma
por: Guo, Mengjie, et al.
Publicado: (2019)

NAT10 promotes cell proliferation by acetylating CEP170 mRNA to enhance translation efficiency in multiple myeloma
por: Wei, Rongfang, et al.
Publicado: (2022)

Steroid 5α-Reductase Type I Induces Cell Viability and Migration via Nuclear Factor-κB/Vascular Endothelial Growth Factor Signaling Pathway in Colorectal Cancer
por: Wei, Rongfang, et al.
Publicado: (2020)

Modified Pulsatillae decoction inhibits DSS-induced ulcerative colitis in vitro and in vivo via IL-6/STAT3 pathway
por: Huangfu, Shaohua, et al.
Publicado: (2020)

Bioactive Compounds from Abelmoschus manihot L. Alleviate the Progression of Multiple Myeloma in Mouse Model and Improve Bone Marrow Microenvironment
por: Hou, Jianhao, et al.
Publicado: (2020)

Drug Targeting of Genomic Instability in Multiple Myeloma
por: Beksac, Meral, et al.
Publicado: (2020)

Extramedullary disease in multiple myeloma: a systematic literature review
por: Bladé, Joan, et al.
Publicado: (2022)

Aldose reductase interacts with AKT1 to augment hepatic AKT/mTOR signaling and promote hepatocarcinogenesis
por: Zhao, Jia-Xing, et al.
Publicado: (2017)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

mTOR: An attractive therapeutic target for osteosarcoma?
por: Ding, Liu, et al.
Publicado: (2016)

Chromosomal instability and acquired drug resistance in multiple myeloma
por: Wang, Wang, et al.
Publicado: (2017)

Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2018)

Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2019)

Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma
por: Lamanuzzi, Aurelia, et al.
Publicado: (2018)

mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein
por: Guglielmelli, Tommasina, et al.
Publicado: (2015)

First Experience of (11)C-Methionine PET in Multiple Myeloma in Turkey
por: Özkan, Elgin, et al.
Publicado: (2022)

Adiponectin inhibits the differentiation and maturation of osteoclasts via the mTOR pathway in multiple myeloma
por: Liu, Zhaoyun, et al.
Publicado: (2020)

Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto?
por: Bakanay, Sule Mine, et al.
Publicado: (2012)

MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway
por: Xiang, Ru-Fang, et al.
Publicado: (2017)

A Rare Extramedullary Presentation of Multiple Myeloma: Paraspinal Muscle Involvement Revealed by FDG PET/CT
por: Özkan, Elgin, et al.
Publicado: (2021)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib
por: Ataca Atilla, Pınar, et al.
Publicado: (2019)

4.4 Å Resolution Cryo-EM structure of human mTOR Complex 1
por: Yang, Huirong, et al.
Publicado: (2016)

The Translational Regulation in mTOR Pathway
por: Yang, Miaomiao, et al.
Publicado: (2022)

Glycolysis is suppressed by DCZ0801-induced inactivation of the Akt/mTOR pathway in Multiple Myeloma
por: Feng, Qilin, et al.
Publicado: (2020)

Combination Treatment Targeting mTOR and MAPK Pathways Has Synergistic Activity in Multiple Myeloma
por: Sun, Kaiyan, et al.
Publicado: (2023)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

Roles of mTOR Signaling in Tissue Regeneration
por: Wei, Xiangyong, et al.
Publicado: (2019)

mTOR Signaling in Metabolic Stress Adaptation
por: Wu, Cheng-Wei, et al.
Publicado: (2021)

Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells
por: Heinemann, Luca, et al.
Publicado: (2022)

DAZAP1 facilitates the alternative splicing of KITLG to promote multiple myeloma cell proliferation via ERK signaling pathway
por: Zhou, Yanyan, et al.
Publicado: (2022)

Polydatin regulates proliferation, apoptosis and autophagy in multiple myeloma cells through mTOR/p70s6k pathway
por: Yang, Baojun, et al.
Publicado: (2017)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Regulation of Osteoclast Growth and Fusion by mTOR/raptor and mTOR/rictor/Akt
por: Tiedemann, Kerstin, et al.
Publicado: (2017)

Escaping mTOR inhibition for cancer therapy: Tumor suppressor functions of mTOR
por: Villar, Victor H., et al.
Publicado: (2017)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nhmb0o2rj5uee0ulfhati443ai